The Phase II THULITE trial will analyze the safety and efficacy of BI 1815368, an investigational oral therapy designed to ...

Accelerated approval was based on results from the Phase I/II LINKER-MM1 trial, which showed a 70% objective response rate in ...

Results from the Phase III ZENITH trial show that patients treated with Winrevair (sotatercept-csrk) for pulmonary arterial ...

Expert panelists emphasize the importance of trusted data sources, strong payer partnerships, economic incentives, and ...

Lunit and Microsoft are working together to push for the use of AI in cancer diagnosis. Lunit and Microsoft are working ...

It’s the caliber of leadership that brings teams together, demands accountability, and drives purposeful, decisive action.

What’s impacting medical affairs today is the update to drug approvals: there’s more visibility, more scrutiny, and more ...

Due to popularity of the medications, GLP-1s were in short supply up until recently. Obesity is a common issue among ...

Pharmaceutical Executive: How is federal policy reshaping life sciences investments? John Stanford: Federal policy is ...

Mike Hollan is an assistant managing editor for Pharmaceutical Executive and Medical Device and Technology and can be reached at mhollan@mjhlifesciences.com.

Updated label allows Neuraceq to be used in selecting patients for amyloid-targeting therapies and includes the use of ...

The supplemental premarket approval application is supported by Phase III data, which showed significant improvements in neck ...